Clinical trial
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is…
NCT00066508 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00066508 |
|---|---|
| Title | Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy |
| Official title | A Phase II Study Of PS-341 (VELCADE) In Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 7 |
| Start date | May 1, 2003 |
| Primary completion | Jul 1, 2005 |
| First posted | Aug 7, 2003 |
| Last update posted | Jan 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: